(The Defender) A military whistleblower released a series of documents revealing 601 deaths of military service members and a high rate of serious adverse events in clinical trials involving remdesivir, an antiviral commonly administered to COVID-19 patients during the pandemic.
According to “The Remdesivir Papers,” some clinical trials were improperly run. In the case of at least one study, results were never made public. The whistleblower also alleged a widespread lack of informed consent for trial participants.
“Data derived from the Department of Defense [DOD] Joint Trauma System … by a military whistleblower offers a stark contrast to results of multiple clinical trials involving the liberal usage of remdesivir in military treatment facilities and other civilian facilities, as well as its potential contribution to, at minimum, hundreds of untimely deaths,” the documents state.
Yet according to the documents, the military began “liberally” administering remdesivir to service members who were suspected of having COVID-19 — months before the U.S. Food and Drug Administration (FDA) approved the drug.
The whistleblower, known by the pseudonym Daniel LeMay, shared the documents with investigative journalist J.M. Phelps, who published them last week in The Gateway Pundit.
In interviews with The Defender, LeMay and Phelps discussed the documents and their significance.
LeMay said the DOD’s Joint Trauma System is responsible for tracking “all sorts of patient data.” He told The Defender that the “initial trial depicted data manipulation in favor of remdesivir.”
He also said that based on his analysis of the data, several clinical trials did not have a true placebo group for which results could be compared with the remdesivir-receiving group. “The primary issue is with patient data. If we can’t verify the placebo group … then we can’t determine the actual efficacy of remdesivir.”
Reacting to the revelations, Brian Hooker, Ph.D., chief scientific officer for Children’s Health Defense, told The Defender:
“All of the information here needs to be made public and the public officials, including Tony Fauci, need to be held to account for the criminal acts associated with the fraudulent ‘trials’ of ivermectin and hydroxychloroquine that were tainted in order to preclude their use, and making remdesivir the standard of care despite the obvious data showing that it kills people.”
Former victims of the COVID-19 hospital protocols, which included administration of remdesivir, and advocates for those victims welcomed the documents’ release.
Gail Seiler, Texas chairperson of the FormerFedsGroup Freedom Foundation, escaped from a Texas hospital in 2021, where she was given remdesivir and listed as “Do Not Resuscitate” against her and her family’s stated wishes. She said “The Remdesivir Papers” only “scratch the surface as to the homicide toll in military hospitals.”
The documents “tell us that our government orchestrated the needless deaths of COVID patients who did not need to die,” Seiler said.
Charlene Delfico, New Jersey state chair of FormerFedsGroup, previously told The Defender that COVID-19 protocols, including remdesivir, implemented at a New Jersey hospital “ran roughshod” over her parents. She said the new documents “validate our grievances regarding remdesivir and the ‘out the window’ standard of care protocol put in place by our government.”
“The whistleblower highlights what we’ve been saying all along,” Delfico said. “This drug is dangerous, and in most cases, fatal. There’s been no transparency or oversight. This should enrage people and make them push for an immediate investigation by Congress.”
“While people were dying, their deaths were being unlawfully labeled COVID deaths — when the deaths should have been attributed to the treatment protocol,” LeMay told The Gateway Pundit.
Military administered remdesivir despite known risks, leading to 601 deaths
According to the whistleblower’s data, 941 military service members died between March 2020 and March 2024. Of those, 63.9%, or 601 service members, were treated with remdesivir. Deaths peaked between November 2020 and July 2021.
“While the military is only a subset of the larger population, it’s clear that service members and veterans who contracted severe COVID and were subsequently treated with remdesivir had a much higher chance of dying,” the documents state.
According to the documents, the DOD administered remdesivir to service members — despite the drug’s known risks and dangers.
“Gilead had already created a monopoly on the drug” with a U.S. patent it secured in 2017 “valid for up to 20 years,” the documents noted.
The drug, developed to treat Ebola, “was subsequently proven to be lethal in human patients.” According to a 2019 New England Journal of Medicine article, remdesivir resulted in the highest mortality rate among four investigational therapies for Ebola administered in the Democratic Republic of Congo — with 53.1% of patients dying.
In 2017, the documents noted, two University of North Carolina researchers, including Ralph Baric, Ph.D., received a $6 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), then headed by Dr. Anthony Fauci, to “accelerate the development of a promising new drug (remdesivir) in the fight against deadly coronaviruses.”
Despite its deadly history, in February 2020, Gilead Sciences received FDA approval to initiate two Phase 3 clinical trials to evaluate the efficacy of remdesivir in treating COVID-19.
